At MUTABILIS, we develop a novel class of antibacterials named Dabocins and derived from the non-natural Diazabicyclooctane scaffold. Dabocins inhibit the Penicillin-Binding Proteins (PBP) like b-lactams, and share their excellent bactericidal properties. Unlike b-lactams, Dabocins show an exceptional stability to class A, B, C, D beta-lactamases, and are thus highly potent against problematic carbapenem-resistant isolates.

Our pipeline includes 2 Dabocin programs:

EBL-1463 (i.v.) – Enterobacterales

EBL-1463 is a potential first-in-class representative of the Dabocin family, entering preclinical development against Enterobacterales. This compound is impervious to any b-lactamase-based resistance so far tested. Moreover, it is unaffected by the PBP3 mutations recently observed in E. coli (Alm, 2015) and with a worrying prevalence in India (Periasamy 2020). This program is supported by CARB-X.

2G-Dabocins (i.v.) – Enterobacterales and non-fermenters

This Lead-to-Candidate program aims at identifying a next generation Dabocin covering both Enterobacterales and non-fermenters such as P. aeruginosa and A. baumannii.

This program is supported by the Novo Holdings Repair Impact fund and by Roche.